Saturday 17 October 2026
Export WOK’s income statement to Excel — free account
WORK Medical Technology Group LTD
WOK Healthcare Medical Devices
WORK Medical Technology Group LTD’s revenue for fiscal 2025 (year ended September 2025) was $9.8 million, down 14.4% from fiscal 2024. Insiders bought in the last twelve months.
1.09
0.25
−18.66%
Follow WOK
| Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 7 | — | — |
Altman Z-Score |
1,088.09 | 19,424.02 | — | — | — |
Altman Z″-Score (non-manufacturers) |
3.51 | 0.75 | 2.45 | 2.80 | 2.85 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(1.72) | (2.31) | (1.69) | (1.89) | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(50.04) | (1.80) | 0.00 | 0.00 | 0.00 |
EV/FCF |
(0.24) | (0.44) | 0.00 | 0.00 | 0.00 |
Quick Ratio |
1.29 | 0.56 | 0.49 | 0.33 | 0.33 |
Current Ratio |
1.71 | 1.03 | 1.17 | 1.17 | 1.17 |
Net Debt/EBITDA |
(1.46) | (2.42) | 3.57 | 1.33 | (0.94) |
Debt/Assets |
19.28% | 36.75% | 29.51% | 23.39% | 0.00% |
Debt/Equity |
0.30 | 0.83 | 0.80 | 0.53 | 0.00 |
Asset Turnover |
0.28 | 0.35 | 0.49 | 0.77 | 0.00 |
Operating CF/Net income |
(5.82) | 0.64 | 19.73 | (2.61) | 0.00 |
Capex/Depreciation |
(0.93) | (6.43) | (0.36) | (0.43) | — |
Interest Coverage |
(4.96) | (7.25) | 1.05 | 1.82 | 2.34 |
| (5.76%) | (25.82%) | 1.01% | 8.36% | 0.00% | |
| (3.09%) | (10.55%) | 0.40% | 3.39% | 0.00% | |
ROIC |
(6.65%) | (11.27%) | 1.42% | 2.43% | 4.93% |
Return on Tangible Assets |
(5.62%) | (29.06%) | 1.14% | 8.45% | 8.45% |
Average Days of Receivables |
422.57 | 138.18 | 203.67 | 73.96 | 73.96 |
Research and Development Expense of Revenue |
4.42% | 2.63% | 2.22% | 0.93% | 0.00% |
Selling, General and Administrative Expense of Revenue |
44.73% | 57.46% | 25.28% | 18.25% | 18.25% |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.04 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
33.98 | 90.53 | 1.09 | 1.58 | 0.00 |
Operating CF per Share |
21.55 | (17.53) | 0.18 | (0.18) | — |
Capex per Share |
(2.97) | (71.31) | (0.05) | (0.11) | — |
Free Cash Flow per Share |
18.58 | (88.84) | 0.13 | (0.29) | — |
Cash per Share |
14.11 | 54.74 | 0.13 | 0.06 | 0.00 |
Shareholders Equity per Share |
73.03 | 126.44 | 0.88 | 0.90 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
73.03 | 126.44 | 0.88 | 0.90 | 0.00 |
Free Cash Flow |
5.38 | (11.29) | 1.63 | (3.67) | — |
Working Capital |
8.48 | 0.65 | 3.23 | 2.35 | 2.35 |
Capital Expenditures |
(0.86) | (9.06) | (0.58) | (1.41) | — |
Net Current Asset Value |
8.46 | 0.65 | 3.18 | 2.26 | 2.26 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.09 | 0.79 | 0.04 | 0.07 | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
0.09 | 0.12 | 0.24 | 0.41 | 0.00 |
Cash ROIC |
17.02% | (31.06%) | 7.58% | (20.46%) | 0.00% |
Accounts Receivable Turnover |
1.25 | 1.93 | 2.35 | 4.94 | 0.00 |
Accounts Payable Turnover |
4.66 | 3.16 | 2.63 | 0.00 | 0.00 |
Inventory Turnover |
2.66 | 2.21 | 2.10 | 3.51 | 0.00 |
Average Days of Payables |
83.89 | 63.26 | 153.46 | 76.44 | 0.00 |
Days of Inventory on Hand |
119.44 | 134.54 | 178.96 | 104.02 | 104.02 |
Average Receivables |
7.88 | 5.96 | 5.78 | 3.99 | — |
Average Payables |
1.61 | 2.73 | 3.58 | — | — |
Average Inventory |
2.82 | 3.90 | 4.49 | 4.36 | — |
Average Assets |
34.70 | 33.10 | 27.75 | 25.54 | — |
Average Common Equity |
18.62 | 13.53 | 11.09 | 10.35 | — |
Columns are period end dates